Literature DB >> 31897587

Noninvasive PET tracking of post-transplant gut microbiota in living mice.

Yanpu Wang1, Chenran Zhang1, Jianhao Lai1, Yang Zhao1, Dehua Lu1, Rui Bao1, Xun Feng1, Ting Zhang1, Zhaofei Liu2.   

Abstract

PURPOSE: The role that gut microbiota plays in determining the efficacy of the anti-tumor effect of immune checkpoint inhibitors is gaining increasing attention, and fecal bacterial transplantation has been recognized as a promising strategy for improving or rescuing the effect of immune checkpoint inhibition. However, techniques for the precise monitoring of in vivo bacterial behaviors after transplantation are limited. In this study, we aimed to use metabolic labeling and subsequent positron emission tomography (PET) imaging to track the in vivo behaviors of gut bacteria that are responsible for the efficacy of anti-PD-1 therapy in living mice.
METHODS: The antitumor effect of anti-PD-1 blockade was tested in a low-response 4T1 syngeneic mouse model with or without fecal transplantation and with or without broad-spectrum antibiotic imipenem treatment. High-throughput sequencing analyses of 16S rRNA gene amplicons in feces of 4T1 tumor-bearing mice pre- and post-anti-PD-1 treatment were performed. The identified bacteria, Bacteroides fragilis (B. fragilis), were labeled with 64Cu and fluorescence dye by the metabolic labeling of N3 followed by click chemistry. In vivo PET and optical imaging of B. fragilis were performed in mice after oral gavage.
RESULTS: The disturbance of gut microbiota reduced the efficacy of anti-PD-1 treatment, and the combination of B. fragilis gavage and PD-1 blockade was beneficial in rescuing the antitumor effect of anti-PD-1 therapy. Metabolic oligosaccharide engineering and biorthogonal click chemistry resulted in successful B. fragilis labeling with 64Cu and fluorescence dye with high in vitro and in vivo stability and no effect on viability. PET imaging successfully detected the in vivo behaviors of B. fragilis after transplantation.
CONCLUSION: PET tracking by metabolic labeling is a powerful, noninvasive tool for the real-time tracking and quantitative imaging of gut microbiota. This strategy is clinically translatable and may also be extended to the PET tracking of other functional cells to guide cell-based adoptive therapies.

Entities:  

Keywords:  64Cu; Gut microbiota; Metabolic labeling; Molecular imaging; PET tracking

Mesh:

Substances:

Year:  2020        PMID: 31897587     DOI: 10.1007/s00259-019-04639-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

Review 1.  Scaling down imaging: molecular mapping of cancer in mice.

Authors:  Ralph Weissleder
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

Review 2.  De-novo and acquired resistance to immune checkpoint targeting.

Authors:  Nicholas L Syn; Michele W L Teng; Tony S K Mok; Ross A Soo
Journal:  Lancet Oncol       Date:  2017-12       Impact factor: 41.316

3.  A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer.

Authors:  Duo Gao; Liquan Gao; Chenran Zhang; Hao Liu; Bing Jia; Zhaohui Zhu; Fan Wang; Zhaofei Liu
Journal:  Biomaterials       Date:  2015-03-14       Impact factor: 12.479

4.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

Review 5.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Hiroto Hatabu; F Stephen Hodi
Journal:  Nat Rev Clin Oncol       Date:  2017-06-27       Impact factor: 66.675

Review 6.  Metabolic oligosaccharide engineering: perspectives, applications, and future directions.

Authors:  Christopher T Campbell; Srinivasa-Gopalan Sampathkumar; Kevin J Yarema
Journal:  Mol Biosyst       Date:  2007-01-12

7.  In vivo imaging and tracking of host-microbiota interactions via metabolic labeling of gut anaerobic bacteria.

Authors:  Naama Geva-Zatorsky; David Alvarez; Jason E Hudak; Nicola C Reading; Deniz Erturk-Hasdemir; Suryasarathi Dasgupta; Ulrich H von Andrian; Dennis L Kasper
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

8.  Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer.

Authors:  Marion Lenoir; Silvina Del Carmen; Naima G Cortes-Perez; Daniel Lozano-Ojalvo; Diego Muñoz-Provencio; Florian Chain; Philippe Langella; Alejandra de Moreno de LeBlanc; Jean Guy LeBlanc; Luis G Bermúdez-Humarán
Journal:  J Gastroenterol       Date:  2016-01-09       Impact factor: 7.527

9.  Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group.

Authors:  Y Aso; H Akazan
Journal:  Urol Int       Date:  1992       Impact factor: 2.089

10.  Bioorthogonal chemistry: fishing for selectivity in a sea of functionality.

Authors:  Ellen M Sletten; Carolyn R Bertozzi
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

View more
  1 in total

Review 1.  Microbiota-microglia connections in age-related cognition decline.

Authors:  Rui Zhou; Shufang Qian; William C S Cho; Jinyun Zhou; Chentao Jin; Yan Zhong; Jing Wang; Xiaohui Zhang; Zhoujiao Xu; Mei Tian; Lawrence W C Chan; Hong Zhang
Journal:  Aging Cell       Date:  2022-03-29       Impact factor: 11.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.